Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by Felcoon Jul 07, 2017 10:33pm

355 Views

Post# 26446523

RE:Scotiabank

Sorry, forgot to paste the opening paragraph.

OUR TAKE: We believe that following PLI's ~$53M equity raise the company is in a stronger financial position to negotiate partnership agreements for PBI-4050 and its pipeline of plasma-derived products. That said, given the company's current burn rate, in the absence of closing deals with upfront payments or obtaining a priority review voucher with the approval of plasminogen (Pg) which could be sold, PLI will likely require an additional $50M+ to reach breakeven. Despite the continued financing risk and a lowered expectation for initial Pg sales, we continue to believe PLI's assets are worth materially more than the share price is reflecting at current levels. As a result, while we have lowered our target price to $4.00 from $4.75, we maintain our Sector Outperform rating and note that material upside to our base case remains in play.

Bullboard Posts

F3 Uranium yields ultra-high grades in Saskatchewan